Compare Synopsys, Inc. (SNPS) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synopsys, Inc. vs TG Therapeutics Inc — how do they compare? Synopsys, Inc. trades at $398.8 (market cap $75.36B), while TG Therapeutics Inc trades at $54.77 (market cap $8.36B). The key difference: Synopsys, Inc. is far larger — about 9× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Synopsys, Inc. nearer its low. Which is the better fit depends on your goals.
| SNPS | TGTX | |
|---|---|---|
Market Cap | $75.36B | $8.36B |
Sector | Technology | Health |
52-Week High | $534.56 | $59.06 |
52-Week Low | $372.33 | $26.94 |
Enterprise Value | $82.59B | $8.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Synopsys (SNPS) trades at $392.03, down 0.46% on the day, with a bearish technical signal from moving averages but strong fundamental performance including three consecutive quarterly EPS beats. Revenue reached $7.05B in 2025 with an 11.43% net income margin, though valuation ratios like a P/E of 68.42 appear elevated. Recent news highlights its critical role in AI chip design and integration benefits from the Ansys acquisition.
The outlook is supported by Wall Street's bullish consensus with a $541.88 price target, but risks include high valuation sensitivity, competitive pressures in semiconductor software, and macroeconomic headwinds. Earnings growth and execution on raised 2026 guidance are key catalysts for upside.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
